 EMERYVILLE, Calif., Sept. 16, 2021 GLOBE NEWSWIRE -- Gritstone bio, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies and vaccines, today announced a 55.0 million private investment in public equity PIPE financing from the sale of 5,000,000 shares of its common stock at a price per share of 11.00. Gross proceeds from the PIPE financings total 55.0 million, before deducting placement agent fees and offering expenses. The PIPE is being led by Frazier Life Sciences Public Fund, with additional participation from Redmile Group and Gilead Sciences. 